Women on semaglutide plus hormone therapy lost about 25 pounds over two years versus 23 without it, researchers reported. Tirzepatide users saw no lasting difference.
Recap by typeshit. Full story at health.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
The Apothecary Pharma recall of compounded tirzepatide and recent FDA moves have patients asking whether their copycat shots are safe.
The dermatologist says many of her patients take GLP-1s, and calls her own weight loss on Zepbound, which she nicknames vitamin Z, life-changing.
Loading…